peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

GLP-1/glucagon dual agonist

Efinopegdutide

Published evidence · coverage incomplete

Anatomy in the research

Anatomy evidence is still being assembled.

These are anatomical mentions in cited research—not established treatment targets or proof of benefit in people.

This publication has no anatomy passages that meet our source-linking checks yet. Read the available findings ↓

General anatomy view only. No peptide-specific structures are highlighted.

At a glance

What is it—and why does it matter?

Efinopegdutide co-agonizes the GLP-1 receptor and the glucagon receptor. In this trial, both groups had LS mean percent reductions in body weight at Week 24; efinopegdutide showed 8.5% vs 7.1% for semaglutide, with p = 0.085.

Sources for this introduction: [1] [2]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

In the source classification, efinopegdutide’s molecule type is protein.

Sources[1]chembl-moleculeEFINOPEGDUTIDEMolecule type: Protein
Molecular / pharmacology evidence

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Molecule type: Protein”

    EFINOPEGDUTIDE · Molecule identity

    chembl-molecule:chembl4297576:1fe59cefe66e:1fe59cefe66e

Identity

Efinopegdutide co-agonizes the GLP-1 receptor and the glucagon receptor.

Sources[2]pubmedA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD).
Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD).”

    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · BACKGROUND & AIMS

    pubmed:37355043:39d713ad5d40:39d713ad5d40

How does it work?

Target, response, and disposition.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

What has been studied?

What the evidence says.

Comparative evidence

The study design is explicitly described as phase IIa, randomized, active-comparator-controlled, parallel-group, and open-label.

Sources[2]pubmedA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.This was a phase IIa, randomized, active-comparator-controlled, parallel-group, open-label study.
Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “This was a phase IIa, randomized, active-comparator-controlled, parallel-group, open-label study.”

    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · METHODS

    pubmed:37355043:39d713ad5d40:39d713ad5d40

Study findings

The baseline comorbidity distribution reported that 33.1% of randomized participants had concurrent T2DM.

Sources[2]pubmedA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.Among 145 randomized participants (efinopegdutide n = 72, semaglutide n = 73), 33.1% had T2DM.
Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Among 145 randomized participants (efinopegdutide n = 72, semaglutide n = 73), 33.1% had T2DM.”

    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · RESULTS

    pubmed:37355043:39d713ad5d40:39d713ad5d40

Study findings

The conclusion states that efinopegdutide 10 mg once weekly produced a significantly greater reduction in liver fat content than semaglutide 1 mg once weekly in NAFLD.

Sources[2]pubmedA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.In patients with NAFLD, treatment with efinopegdutide 10 mg weekly led to a significantly greater reduction in LFC than semaglutide 1 mg weekly.
Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “In patients with NAFLD, treatment with efinopegdutide 10 mg weekly led to a significantly greater reduction in LFC than semaglutide 1 mg weekly.”

    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · CONCLUSIONS

    pubmed:37355043:39d713ad5d40:39d713ad5d40

Study findings

In this randomized comparison, efinopegdutide produced a larger relative reduction in MRI-estimated liver fat content at Week 24 than semaglutide, with LS mean 72.7% vs 42.3% (90% CIs reported; p <0.001).

Sources[2]pubmedA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.The least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8-78.7]) than with semaglutide (42.3% [90% CI 36.5-48.1]).
Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8-78.7]) than with semaglutide (42.3% [90% CI 36.5-48.1]).”

    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · RESULTS

    pubmed:37355043:39d713ad5d40:39d713ad5d40

Study findings

In this trial, both groups had LS mean percent reductions in body weight at Week 24; efinopegdutide showed 8.5% vs 7.1% for semaglutide, with p = 0.085.

Sources[2]pubmedA phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease.Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs. semaglutide 7.1%; p = 0.085).
Human research · design must be checked

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs. semaglutide 7.1%; p = 0.085).”

    A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. · RESULTS

    pubmed:37355043:39d713ad5d40:39d713ad5d40

Risks and interactions

Risks, organized for scanning.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Products and regulatory status

Same ingredient. Different records.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Administration context

The practical clinical context.

This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.

Additional research & classification gaps

5 archived statements are kept separate from drug-effect findings. Media studies, economic models, methods, and records with unresolved scope are not used as medical-effect evidence.

Inspect contextual research (5)
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

One listed synonym for efinopegdutide is HM-12525A.

Research context only—not evidence of a treatment effect.

  • EFINOPEGDUTIDE
    Efinopegdutida; Efinopegdutide; HM-12525A; HM12525A; Jnj-64565111; JNJ-64565111
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

One listed synonym for efinopegdutide is Jnj-64565111.

Research context only—not evidence of a treatment effect.

  • EFINOPEGDUTIDE
    Efinopegdutida; Efinopegdutide; HM-12525A; HM12525A; Jnj-64565111; JNJ-64565111
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

ChEMBL lists EFINOPEGDUTIDE as the preferred name for CHEMBL4297576.

Research context only—not evidence of a treatment effect.

Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

One listed synonym for efinopegdutide is HM12525A.

Research context only—not evidence of a treatment effect.

  • EFINOPEGDUTIDE
    Efinopegdutida; Efinopegdutide; HM-12525A; HM12525A; Jnj-64565111; JNJ-64565111
Research context · scope unclassified

1 cited source · Study independence not established

How to read this evidence

Sources and study IDs describe provenance, not clinical strength. Several articles can report the same study; one study can support several distinct findings. No clinical strength rating has been assigned here.

1 cited passage across 1 source record. 1 publication group(s) lack a resolved study identity.

In ChEMBL, efinopegdutide is indexed under the identifier CHEMBL4297576.

Research context only—not evidence of a treatment effect.

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: administration, contraindication, interaction, mechanism, regulatory, safety
  • 145 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (61), assurance_score_below_0.72 (82), current_regulatory_source_required (31), extraction_ambiguity (19), high_risk_requires_regulatory_or_two_independent_sources (82), no_direct_support (142), proposal_not_staged (4)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. EFINOPEGDUTIDE ↗

    chembl-molecule · published 2026-08-26 · retrieved 2026-08-26T08:42:26Z

  2. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. ↗

    pubmed · published 2023-10-01 · retrieved 2026-09-04T19:33:20Z

Publication history and provenance

Version 2 · Automated assessment · 2026-09-04T19:33:20Z

26e56ea0133b64b4e006af0ff948e5b5385bc8163086fa93f22a899821fbc510